Hosted on MSN1mon
Vanda Pharmaceuticals targets $1B revenue by 2030 with expanded psychiatry portfolioCEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% year-over-year. He ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback